Evidence map›Paper›PMID 25118276›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

KLRG+ invariant natural killer T cells are long-lived effectors.

Kanako Shimizu, Yusuke Sato, Jun Shinga, Takashi Watanabe, Takaho Endo, Miki Asakura, Satoru Yamasaki, Kazuyoshi Kawahara, Yuki Kinjo, Hiroshi Kitamura and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Tuberculosis in Pregnancy: Challenges of Immune Protection.The Journal of infectious diseases · 2026
    Review
  4. Metabolic control of innate-like T cells.Nature reviews. Immunology · 2026
    Review
  5. Review
  6. Article
  7. IL-27 regulates the differentiation of follicular helper NKT cells via metabolic adaptation of mitochondria.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Triphasic production of IFNDiscovery immunology · 2023
    Article
  15. Review
  16. Article
  17. Article
  18. Glycolipid-peptide conjugate vaccines elicit CD8Clinical & translational immunology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Kanako ShimizuLaboratories for Immunotherapy.
Yusuke SatoLaboratories for Immunotherapy.
Jun ShingaLaboratories for Immunotherapy.
Takashi WatanabeIntegrative Genomics.
Takaho EndoIntegrative Genomics.
Miki AsakuraLaboratories for Immunotherapy.
Satoru YamasakiLaboratories for Immunotherapy.
Kazuyoshi KawaharaDepartment of Applied Material and Life Science, College of Engineering, Kanto Gakuin University, Yokohama 236-8501, Japan;
Yuki KinjoDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; and.
Hiroshi KitamuraIntegrative Genomics.
Hiroshi WataraiImmune Regulation, and.
Yasuyuki IshiiVaccine Design, RIKEN Center for Integrative Medical Sciences, Kanagawa, Yokohama 230-0045, Japan;
Moriya TsujiHIV and Malaria Vaccine Program, Aaron Diamond AIDS Research Center, Affiliate of The Rockefeller University, New York, NY 10016.
Masaru TaniguchiImmune Regulation, and.
Osamu OharaIntegrative Genomics.
Shin-ichiro FujiiLaboratories for Immunotherapy, fujiis@rcai.riken.jp.
Genomics (United Kingdom) · GBKanto Gakuin University · JPNational Institute of Infectious Diseases · JPRIKEN Center for Integrative Medical Sciences · JPRockefeller University · US

Funding

CD1d/NKT-binding glycolipids in enhancing the immunogenicity of a malaria vaccineR01AI070258 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI TSUJI, MORIYA · 2012 to 2016
$2.2M
CD1d/NKT-binding Glycolipids as an Adjuvant for a T cell-based Malaria VaccineR56AI070258 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI TSUJI, MORIYA · 2008 to 2009
$934k
NIAID NIH HHS AI070258NIAID NIH HHS R01 AI070258NIAID NIH HHS R56 AI070258
6 · The paper itself

Abstract

Immunological memory has been regarded as a unique feature of the adaptive immune response mediated in an antigen-specific manner by T and B lymphocytes. However, natural killer (NK) cells and γδT cells, which traditionally are classified as innate immune cells, have been shown in recent studies to have hallmark features of memory cells. Invariant NKT cell (iNKT cell)-mediated antitumor effects indicate that iNKT cells are activated in vivo by vaccination with iNKT cell ligand-loaded CD1d(+) cells, but not by vaccination with unbound NKT cell ligand. In such models, it previously was thought that the numbers of IFN-γ-producing cells in the spleen returned to the basal level around 1 wk after the vaccination. In the current study, we demonstrate the surprising presence of effector memory-like iNKT cells in the lung. We found long-term antitumor activity in the lungs of mice was enhanced after vaccination with iNKT cell ligand-loaded dendritic cells. Further analyses showed that the KLRG1(+) (Killer cell lectin-like receptor subfamily G, member 1-positive) iNKT cells coexpressing CD49d and granzyme A persisted for several months and displayed a potent secondary response to cognate antigen. Finally, analyses of CDR3β by RNA deep sequencing demonstrated that some particular KLRG1(+) iNKT-cell clones accumulated, suggesting the selection of certain T-cell receptor repertoires by an antigen. The current findings identifying effector memory-like KLRG1(+) iNKT cells in the lung could result in a paradigm shift regarding the basis of newly developed extrathymic iNKT cells and could contribute to the future development of antitumor immunotherapy by uniquely energizing iNKT cells.

Indexed as

AnimalsCell SurvivalComplementarity Determining RegionsDendritic CellsGalactosylceramidesGranzymesImmunologic MemoryIntegrin alpha4Interferon-gammaLectins, C-TypeLungLymphocyte ActivationMiceNatural Killer T-CellsReceptors, Antigen, T-Cell, alpha-betaReceptors, Immunologicalpha-galactosylceramideComplementarity Determining RegionsGalactosylceramidesGranzymesIntegrin alpha4Interferon-gammaKlrg1 protein, mouseLectins, C-TypeReceptors, Antigen, T-Cell, alpha-betaReceptors, Immunologic

Identifiers

PMID25118276
PMCPMC4151776
OpenAlexW2152344302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.